Feature

Surgeon General wants naloxone widely on hand. Is that feasible?


 

Nonprofit organizations and health care providers keenly feel the pressures of increasing demand and cost

Experts say price breaks on naloxone are not sufficient to cover the costs on the ground.

“Sixty-four thousand people lost their lives [nationally in 2016] — that’s someone every 12 minutes,” said Justin Phillips, executive director of Overdose Lifeline, an Indianapolis-based nonprofit. “Ten free kits is not going to be enough.”

Ms. Phillips said her organization relies on generic naloxone, which is the least expensive formulation. It’s the only feasible option, using dedicated grant money the group received from the state attorney general’s office as part of a program funded by a settlement with pharmaceutical companies.

But that money is almost dried up. “We need to be able to access naloxone – which I’m told is pennies to make – for the pennies it cost to make it,” she said.

Ms. Phillips, who worked with Dr. Adams when he ran Indiana’s health department, said she has discussed the need for naloxone funding with the surgeon general, but never its price.

Pages

Recommended Reading

Pot legalization tied to drop in opioid prescribing rates
MDedge Internal Medicine
FDA recalls kratom products for salmonella contamination
MDedge Internal Medicine
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Internal Medicine
Abstract: Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The SUMMIT Randomized Clinical Trial
MDedge Internal Medicine
MDedge Daily News: Skin disorders defeat weekend warriors
MDedge Internal Medicine
Epilepsy upped risk of unnatural death
MDedge Internal Medicine
EAGLES: Smoking cessation therapy did not up cardiovascular risk
MDedge Internal Medicine
Life and health are not even across the U.S.
MDedge Internal Medicine
MDedge Daily News: Shingles boosts stroke risk
MDedge Internal Medicine
Adding CBT to substance use treatment may increase success
MDedge Internal Medicine